Bz Arg-p-nitroanilide | 911-76-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Bz Arg-p-nitroanilide
• 英文别名: N_α-benzoyl-L-arginine 4-nitroanilide hydrochloride；Nα-benzoyl-L-arginine-4-nitroanilide hydrochloride；N_α-benzoyl-L-arginine p-nitroanilide；N^α-Benzoyl-L-arginine-p-nitroanilide；benzoyl-L-arginine-p-nitroanilide hydrochloride；N(α)-benzoyl-L-arginine 4-nitroanilide
• CAS: 911-76-2；6208-93-1；7723-66-2；26056-64-4
• 化学式: C₁₉H₂₂N₆O₄
• 分子量: 398.421
• InChiKey: RKDYKIHMFYAPMZ-INIZCTEOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  29
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  168
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  Bz Arg-p-nitroanilide 在 plasmin from Alcalase 作用下， 以 aq. phosphate buffer 为溶剂， 反应 0.25h， 生成 4-硝基苯胺
  参考文献：
  名称：

  Substrate specificity of glutamyl endopeptidase (GE): Hydrolysis studies with a bovine α-casein preparation

  摘要：

  Glutamyl endopeptidase (GE) from Alcalase (TM) 2.4 L was purified using hydrophobic interaction (HIC) and ion-exchange (IEX) chromatography. The yield of GE obtained was approximately 42%. Bovine alpha-casein (containing alpha(s1)- and alpha(s2)-casein) was digested with GE at 37 and 50 degrees C for 4 h. Samples were withdrawn at various time intervals and the peptides generated were analysed using mass spectrometry. GE activity was highly specific and hydrolysed the peptide bond predominantly on the carboxy side of Glu residues while hydrolysis on the carboxyl side of Asp residues was also observed. Hydrolysis did not occur when Pro was at the P-1' position. In Glu-Glu-X (X = Arg, Asn, Ile and Ser) and Glu-Glu-Glu-Lys sequences, hydrolysis of Glu-X and Glu-Lys was preferred. The results are relevant to our understanding of the hydrolytic specificity of Alcalase, a food-grade proteolytic preparation containing GE activity which is used in the generation of casein hydrolysates. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.foodchem.2012.08.038
• 作为产物：
  描述：

  N-ALPHA-苄酰-L-精氨酸 、 4-硝基苯胺 以 水 、 N,N-二甲基甲酰胺 为溶剂， 生成 Bz Arg-p-nitroanilide
  参考文献：
  名称：

  Acid-sensitive latent inhibitors for proteolytic enzymes: synthesis and characterization

  摘要：

  The reaction between peptide aldehydes and acylhydrazones affords derivatives that represent potential prodrugs for selective inhibition of lysosomal enzymes. BzPheal = Ala, obtained from the reaction between N-benzoyl-L-phenylalaninal and N-acetyl-L-alanine hydrazide, has been most carefully studied. When BzPheal = Ala is introduced into ongoing reactions catalyzed by alpha-chymotrypsin or papain, the rate of these reactions diminishes more rapidly with time than do those of controls lacking BzPheal = Ala. Furthermore, the disparity between run and control is much greater at pH 5 than at pH 7. The extent of inhibition (defined as explained in the text) at pH 5 can exceed that at pH 7 by 25-40-fold. The data are quantitatively explained by a reaction scheme that recognizes three important properties of BzPheal = Ala: (1) It undergoes hydrolysis at pH 5-7 to regenerate N-benzoyl-L-phenylalaninal; (2) the aldehyde thus liberated is a far more potent inhibitor for serine or cysteine proteases than is BzPheal = Ala; and (3) the rate constant for hydrolysis of BzPheal = Ala at pH 5 greatly exceeds that at pH 7.

  DOI：

  10.1021/jm00126a018

文献信息

• Arylalkanoyl derivatives, processes for their preparation, their use and pharmaceutical compositions containing them
  申请人：Aventis Pharma Deutschland GmbH

  公开号：EP1022268A1

  公开（公告）日：2000-07-26

  The present invention relates to new compounds for the inhibition of blood clotting proteins, and more particularly, to arylalkanoyl derivatives of the formula I, wherein R(1), R(2), R(3), R(4), R(5), R(6a) and R(6b) have the meanings indicated in the claims. The compounds of formula I are inhibitors of the blood clotting enzyme factor Xa. The invention also relates to processes for the preparation of the compounds of formula I, to methods of inhibiting factor Xa activity and of inhibiting blood clotting, to the use of the compounds of formula I in the treatment and prophylaxis of diseases, which can be treated or prevented by the inhibition of factor Xa activity such as thromboembolic diseases, to and the use of the compounds of formula I in the preparation of medicaments to be applied in such diseases. The invention further relates to compositions containing a compound of formula I in admixture or otherwise in association with an inert carrier, in particular pharmaceutical compositions containing a compound of formula I together with pharmaceutically acceptable carrier substances and auxiliary substances.

  本发明涉及用于抑制血液凝固蛋白的新化合物，更具体地，是指式I的芳烷酰衍生物， 其中R(1)、R(2)、R(3)、R(4)、R(5)、R(6a)和R(6b)的含义如权利要求中所示。式I的化合物是血液凝固酶因子Xa的抑制剂。本发明还涉及制备式I化合物的方法，抑制因子Xa活性和血液凝固的方法，使用式I化合物治疗和预防可以通过抑制因子Xa活性来治疗或预防的疾病，如血栓栓塞性疾病，以及使用式I化合物制备用于治疗上述疾病的药物。本发明还涉及包含式I化合物的组合物，与惰性载体混合或以其他方式相关联，尤其是包含式I化合物的药物组合物，以及药用可接受的载体物质和辅助物质。
• Pyrazine-derived disulfide-reducing agent for chemical biology
  作者：John C. Lukesh, III、Kelly K. Wallin、Ronald T. Raines

  DOI：10.1039/c4cc04491f

  日期：——

  For fifty years, dithiothreitol (DTT) has been the preferred reagent for the reduction of disulfide bonds in proteins and other biomolecules. Herein we report on the synthesis and characterization of 2,3-bis(mercaptomethyl)pyrazine (BMMP), a readily accessible disulfide-reducing agent with reactivity under biological conditions that is markedly superior to DTT and other known reagents.

  在过去五十年中，二硫苏糖醇（DTT）一直是还原蛋白质和其他生物分子中二硫键的首选试剂。本文报道了2,3-双（巯基甲基）吡嗪（BMMP）的合成与表征，这是一种易于获得的二硫还原剂，其在生物条件下的反应性显著优于DTT及其他已知试剂。
• New blood coagulation factor inhibitors
  申请人：NOVO NORDISK A/S

  公开号：EP1967522A1

  公开（公告）日：2008-09-10

  The invention relates to novel compounds with formula (I) wherein R1-R7 are as herein defined useful as blood coagulation factor inhibitors. The compounds (I) may be used for treatment of thrombotic conditions or as stabilizers of liquid formulations of blood coagulation factors, in particular liquid formulations of FVIIA, Factor VII variants, or Factor VII derivatives.

  该发明涉及具有公式（I）的新化合物，其中R1-R7如本文所定义，可用作血液凝血因子抑制剂。这些化合物（I）可用于治疗血栓性疾病或作为液体血液凝血因子的配方稳定剂，特别是FVIIA、因子VII变体或因子VII衍生物的液体配方。
• [EN] DITHIOAMINE REDUCING AGENTS<br/>[FR] AGENTS RÉDUCTEURS DITHIOAMINE
  申请人：WISCONSIN ALUMNI RES FOUND

  公开号：WO2013123382A1

  公开（公告）日：2013-08-22

  Dithioamine reducing agents useful for the reduction of disulfide bonds. The reducing agents of this invention are useful, for example, to reduce disulfide bonds, particularly in proteins, or to prevent the formation of disulfide bonds, particularly in proteins and other biological molecules. Reducing agents of this invention can be employed to regulate protein function in proteins in which a sulfhydryl group is associated with biological activity. Reducing agents of this invention can prevent inactivation of a given protein or enhance activation of a given protein or other biological molecule in vitro and/or in vivo. Reducing agents of this invention can prevent or reduce oxidation of cysteine residues in proteins and prevent the formation of reduced activity protein dimers (or other oligomers). Reducing agents of this invention are useful and suitable for application in a variety of biological applications, particularly as research and synthetic reagents.

  硫胺类还原剂可用于还原二硫键。该发明的还原剂可用于还原二硫键，特别是蛋白质中的二硫键，或者预防二硫键的形成，特别是在蛋白质和其他生物分子中。该发明的还原剂可用于调节蛋白质功能，其中巯基与生物活性相关。该发明的还原剂可防止给定蛋白质的失活，或增强给定蛋白质或其他生物分子的活化，无论是在体外还是体内。该发明的还原剂可预防或减少蛋白质中半胱氨酸残基的氧化，并防止降低活性蛋白质二聚体（或其他寡聚体）的形成。该发明的还原剂适用于各种生物应用，特别是作为研究和合成试剂。
• Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use
  申请人：——

  公开号：US20020052417A1

  公开（公告）日：2002-05-02

  The present invention relates to compounds of the formula I, 1 in which R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , A, X, m and n have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of thromboembolic diseases and restenoses. They are reversible inhibitors of the blood clotting enzyme factor VIIa and can in general be applied in conditions in which an undesired activity of factor VIIa is present or for the cure or prevention of which an inhibition of factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, for example as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

  本发明涉及公式I的化合物，其中R1、R2、R3、R4、R5、R6、A、X、m和n具有所述声明中指示的含义。公式I的化合物是有价值的药理活性化合物。它们表现出强烈的抗血栓作用，适用于治疗和预防血栓栓塞病和再狭窄症等疾病。它们是血凝酶酶因子VIIa的可逆抑制剂，通常可以应用于存在不良VIIa活性的情况或者为治疗或预防需要抑制VIIa的情况。本发明还涉及制备公式I化合物的方法，以及它们的用途，例如作为药物的活性成分和包含它们的药物制剂。